Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
August 31, 2021
August 31, 2021
Evaluation of Loco-Regional Skin Toxicity Induced by an In Situ Forming Depot after a Single Subcutaneous Injection at Different Volumes and Flow Rates in Göttingen Minipigs
August 26, 2021
August 26, 2021
Impact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology
August 10, 2021
August 10, 2021
Participation terms in the MedinCell Combined General Meeting
August 4, 2021
August 4, 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
July 28, 2021
July 28, 2021
MedinCell announces the initiation of coverage of its stock by ODDO-BHF
July 26, 2021
July 26, 2021
MedinCell announces fiscal year consolidated results April 2020 – March 2021
June 16, 2021
June 16, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
June 14, 2021
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
